Universal Newborn RSV Immunization Could Halve European Infant Hospitalizations

A new multi-model assessment from the European Centre for Disease Prevention and Control (ECDC) projects that universally immunizing newborns against respiratory syncytial virus (RSV) could prevent more than 60 percent of related hospitalizations. The findings offer a concrete strategy to alleviate severe winter pressure on pediatric wards across the continent.[1][2]

RSV is a pervasive respiratory virus that typically causes mild, cold-like symptoms in adults but can trigger severe bronchiolitis and pneumonia in very young children. Across the European Union and European Economic Area, the virus is responsible for an estimated 250,000 pediatric hospital admissions every year.[2][3]

"Protecting infants from RSV in the first months of their life is particularly important," said Bruno Ciancio, the ECDC Head of Unit. He emphasized that health authorities now possess the tools to cut the risk of severe respiratory infections in young children by more than half.[1][3]

The ECDC's collaborative modeling hub, known as RespiCompass, evaluated two primary prevention strategies to achieve this reduction. This platform facilitates international modeling collaboration to address priority public health questions, using standardized scenarios to project the outcomes of different immunization strategies.[2]

Modeling the prevention strategies

Depending on the specific country, RSV infections currently account for between 7 and 52 percent of all pediatric respiratory hospitalizations. This massive variation highlights the uneven burden placed on different national healthcare systems and underscores the need for a continent-wide prevention strategy.[2]

The first preventative approach involves administering long-acting monoclonal antibodies directly to newborns. These laboratory-engineered proteins mimic the immune system's natural ability to fight off harmful pathogens, providing immediate, passive protection without requiring the infant's immature immune system to mount a response.[3]

Under a high-coverage scenario where 90 percent of newborns receive these long-acting antibodies at birth, the models project a 61 percent drop in RSV-related hospitalizations among infants aged zero to two months. The ECDC estimates that the minimum-to-maximum spread across the individual models ranged from a 38 to 85 percent reduction.[1][2][3]

The alternative strategy of maternal vaccination also demonstrated substantial protective effects. If 90 percent of pregnant women receive the RSV vaccine, the resulting transplacental transfer of maternal antibodies is projected to reduce infant hospitalizations by 52 percent over the same critical two-month period.[1][2][3]

Both interventions concentrate their benefits exactly where the clinical vulnerability is greatest. The assessment indicates that approximately 80 percent of the total averted hospitalizations would occur in infants under two months of age, with another 15 percent prevented in those aged three to five months.[2]

Shifting from targeted to universal care

The timing of these findings is critical as Europe enters its traditional respiratory virus season. RSV typically circulates concurrently with influenza and COVID-19, creating a compounding effect that frequently pushes pediatric intensive care units to their operational limits during the winter months.[1][3][4]

Historically, RSV prevention was limited to palivizumab, a short-acting monoclonal antibody introduced in 1999 that required up to five monthly injections. Because of its logistical complexity and high cost, its use was strictly limited to high-risk infants, such as those born prematurely or with severe immunodeficiency.[2]

The landscape shifted significantly in October 2022 when the European Commission authorized nirsevimab, an extended half-life monoclonal antibody that provides protection throughout a full RSV season with a single dose. A second long-acting option, clesrovimab, received European approval in June 2026, expanding the available arsenal.[2]

Maternal vaccination became a viable European strategy in June 2023 with the authorization of a vaccine administered between 24 and 36 weeks of gestation. Clinical data shows this maternal immunization significantly reduces severe RSV-related respiratory infections in infants during their first six months of life.[2]

The ECDC models suggest that long-acting monoclonal antibodies achieve a slightly greater impact per dose than maternal vaccination across all coverage scenarios. This efficiency means fewer newborns need to be immunized with antibodies to prevent a single RSV-related hospitalization, a finding consistent across all ten models used.[2]

The critical role of high coverage

However, the success of either strategy depends heavily on achieving broad population coverage. In a low-coverage scenario of just 20 percent, the projected reduction in hospitalizations plummets to 14 percent for monoclonal antibodies and 12 percent for maternal vaccination, severely limiting the public health benefit.[2]

Several European countries are currently evaluating how to integrate these new prophylactic tools into their national immunization schedules. The ECDC data provides a quantitative foundation for these policy decisions, demonstrating that universal coverage is necessary to achieve a meaningful population-level impact.[2]

The models specifically focused on winter season administration without catch-up campaigns for infants born outside of the peak viral window. This targeted approach maximizes the efficiency of the interventions by aligning the highest levels of protection with the period of most intense viral circulation.[2]

While the clinical benefits are clear, the logistical challenges of implementing universal RSV immunization remain a consideration for national health ministries. Establishing reliable delivery mechanisms in maternity wards and primary care settings will require coordinated public health efforts and sustained funding.[2]

The transition from targeted high-risk prophylaxis to universal infant protection represents a paradigm shift in pediatric respiratory care. The ECDC's projections confirm that widespread adoption of these tools could fundamentally alter the seasonal trajectory of infant respiratory illness, protecting hundreds of thousands of families.[1][2]